| 12.55 -0.555 (-4.24%) | 07-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.05  |
1-year : | 18.74 |
| Resists | First : | 14.59 |
Second : | 16.04 |
| Pivot price | 14.46 |
|||
| Supports | First : | 12.25 |
Second : | 10.19 |
| MAs | MA(5) : | 13.8 |
MA(20) : | 14.65 |
| MA(100) : | 16.85 |
MA(250) : | 18.43 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 25.4 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 30.97 | Low : | 12.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SMMT ] has closed below the lower bollinger band by 0.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SMMT ] is to continue within current trading range. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.08 - 13.16 | 13.16 - 13.21 |
| Low: | 12.07 - 12.17 | 12.17 - 12.24 |
| Close: | 12.42 - 12.57 | 12.57 - 12.68 |
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Tue, 28 Jul 2026
Summit Therapeutics Inc (SMMT) Institutional Confidence - TradingKey
Mon, 27 Jul 2026
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Sun, 26 Jul 2026
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Fri, 24 Jul 2026
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Fri, 24 Jul 2026
Summit Therapeutics Establishes $380 Million ATM Equity Program - The Globe and Mail
Fri, 24 Jul 2026
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 798 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 80.8 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 37,330 (K) |
| Shares Short P.Month | 36,810 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -101.7 % |
| Return on Equity (ttm) | -192.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -458 (M) |
| Levered Free Cash Flow | -140 (M) |
| PE Ratio | -11.31 |
| PEG Ratio | 0 |
| Price to Book value | 17.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|